查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1492517

家族性腺瘤息肉症治療市場：按類型、最終用戶、分銷管道分類 - 全球預測 2024-2030

Familial Adenomatous Polyposis Treatment Market by Type (Aspirin, CEQ-508, Eflornithine Hydrochloride), End-Users (Clinics & Hospitals, Diagnostic Centres, Home Healthcare), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年家族性腺瘤息肉症治療市場規模為11.2億美元，預計2024年將達12億美元，2030年將達18.5億美元，複合年成長率為7.43%。

家族性腺瘤息肉症(FAP) 治療是指管理和控制家族性腺瘤息肉症，家族性腺瘤性息肉病是一種遺傳性疾病，結腸和直腸中出現大量腺瘤性息肉。如果不及時治療，這種遺傳疾病會顯著增加大腸癌的風險。 FAP 治療的目標不僅是控制症狀和預防大腸癌的發展，而且是維持患有這種疾病的人的生活品質。治療計劃通常根據每個患者的需求和情況進行個性化，並專注於最大限度地減少與疾病相關的潛在風險和併發症。公眾意識的提高和基因檢測的改進正在導致更早和更頻繁的診斷，擴大了對 FAP 治療等治療方案的需求。隨著全球大腸直腸癌發生率的增加，人們越來越重視對顯著增加癌症風險的疾病（例如 FAP）的預防性治療。然而，對 FAP 藥物副作用的擔憂以及監管障礙給公司帶來了重大挑戰。相反，對新藥和微創手術技術研發的投資可以顯著地推進治療選擇。遺傳諮詢和個人化醫療的興起提供了根據個人遺傳特徵量身定做治療的機會，有可能改善預後。

主要市場統計
基準年[2023] 11.2億美元
預測年份 [2024] 12億美元
預測年份 [2030] 18.5億美元
複合年成長率（%） 7.43%

區域洞察

在美洲，美國和加拿大處於 FAP 研究和治療的前沿，兩國都開發​​了多項專利技術和創新治療方法。在 FDA 的推動下，美國強大的法律規範支持廣泛的研究和有前途的治療方法的早期開發。兩國的公共和私人醫療保健系統使患者的意識相對較高，並且易於獲得先進的治療方法。同時，歐洲、中東和非洲地區的患者受益於統一的法規環境，有利於新治療方法的快速引入。研究舉措通常得到跨國合作的支持，例如歐洲藥品管理局 (EMA) 推動的合作。高標準的醫療保健和廣泛的公眾意識有助於 FAP 的有效管理和治療。此外，亞太地區的醫療保健能力正在快速成長，中國、日本和印度在 FAP 研發方面佔據重要地位。日本擁有強大的製藥和生物技術領域，因此專注於基因研究和標靶治療藥物的開發。印度正在變得擅長診斷和治療 FAP 等遺傳性疾病。中國龐大的人口和對醫療保健創新的投資使其成為該地區的關鍵參與者。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在家族性腺瘤息肉症治療市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對家族性腺瘤息肉症治療市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在家族性腺瘤息肉症治療市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人們越來越關注人群中的遺傳疾病以及有效治療方法的需求
      • 政府對大腸直腸癌的優先措施及保險報銷政策
    • 抑制因素
      • 政府對 FAP 藥物的嚴格監管和產品召回案例
    • 機會
      • 基因檢測與給藥系統技術創新快速進展
      • 新藥及微創手術技術研發投入
    • 任務
      • FAP 藥物相關嚴重副作用的風險
  • 市場區隔分析
    • 類型：二十碳五烯酸和阿斯匹靈作為發炎藥物在治療家族性腺瘤息肉症(FAP) 中越來越受歡迎
    • 最終用戶：透過醫院和診斷中心擴大家族性腺瘤息肉症治療選擇的可用性
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章家族性腺瘤息肉症治療市場：依類型

  • 阿斯匹靈
  • CEQ-508
  • 鹽酸依氟鳥氨酸
  • 二十碳五烯酸

第7章家族性腺瘤息肉症治療市場：依最終用戶分類

  • 診所和醫院
  • 診斷中心
  • 家庭保健

第8章家族性腺瘤息肉症治療市場：依通路

  • 醫院藥房
  • 零售藥房

第9章北美及南美家族性腺瘤息肉症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區家族性腺瘤息肉症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲家族性腺瘤息肉症治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 硬纖維瘤的突破性治療獲得 FDA核准
    • FDA 授予 Therapyx 的 FAPXIL 孤兒藥資格，用於治療家族性腺瘤息肉症
    • 家族性腺瘤息肉症的里程碑式臨床試驗獲得 FDA核准
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-6B0EA0797510

[184 Pages Report] The Familial Adenomatous Polyposis Treatment Market size was estimated at USD 1.12 billion in 2023 and expected to reach USD 1.20 billion in 2024, at a CAGR 7.43% to reach USD 1.85 billion by 2030.

Familial Adenomatous Polyposis (FAP) treatment refers to the medical interventions and strategies employed to manage and control Familial Adenomatous Polyposis, a hereditary condition characterized by the growth of numerous adenomatous polyps in the colon and rectum. This genetic disorder increases the risk of developing colorectal cancer significantly if left untreated. The objective of FAP treatment is not only to manage symptoms and prevent the development of colorectal cancer but also to maintain the quality of life for those with the condition. Treatment plans are often personalized to fit the needs and circumstances of the individual patient, focusing on minimizing potential risks and complications associated with the disease. Growing awareness among populations and improvements in genetic testing have led to earlier and increased diagnoses, expanding the need for treatment options such as FAP treatment. As colorectal cancer rates rise globally, there is a growing emphasis on preventive treatments for conditions like FAP that significantly raise cancer risk. However, concerns associated with the side effects of FAP medicines, along with the regulatory hurdles, present a significant challenge for the companies. Conversely, investment in the research and development of new drugs and less invasive surgical techniques could significantly advance treatment options. The rise of genetic counseling and personalized medicine approaches offers opportunities to tailor treatments to individual genetic profiles, potentially improving outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 1.12 billion
Estimated Year [2024] USD 1.20 billion
Forecast Year [2030] USD 1.85 billion
CAGR (%) 7.43%

Regional Insights

In the Americas, the United States and Canada are at the forefront of FAP research and treatment, with several patented technologies and innovative therapeutic approaches being developed in both countries. America's strong regulatory framework, facilitated by the FDA, supports extensive research and fast-tracking promising treatments. Both countries ' public and private healthcare systems enable a relatively high level of patient awareness and access to advanced treatment options. At the same time, in EMEA, the patients benefit from a harmonized regulatory environment, which aids in the swift adoption of new treatments. Cross-national collaborations often support research initiatives, such as those facilitated by the European Medicines Agency (EMA). High standards of healthcare and widespread awareness among populations contribute to the effective management and treatment of FAP. Moreover, the Asia Pacific region is experiencing rapid growth in healthcare capabilities, with China, Japan, and India significant in research and treatment development for FAP. Given its robust pharmaceutical and biotechnology sectors, there's a significant focus on genetic research and the development of targeted therapies in Japan. India is becoming more adept at diagnosing and treating hereditary conditions such as FAP. China's vast population and investment in healthcare innovation have also made it a key player in the region.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Familial Adenomatous Polyposis Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Growing concerns related to genetic disorders among populations and the need for effective treatment options
      • Favorable government initiatives and reimbursement policies for colorectal cancer
    • Market Restraints
      • Strict governments regulations for FAP drugs and cases of product recalls
    • Market Opportunities
      • Rapid pace of technological innovation in genetic testing and drug delivery system
      • Investment in the research and development of new drugs and less invasive surgical techniqe
    • Market Challenges
      • Risk of significant side effects associated with the FAP medicines
  • Market Segmentation Analysis
    • Type: Growing preference for icosapent and aspirin as an anti-inflammatory medications in Familial Adenomatous Polyposis (FAP) treatment
    • End-Users: Widening availability of Familial Adenomatous Polyposis treatment options through hospitals and diagnostic centers
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Familial Adenomatous Polyposis Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Familial Adenomatous Polyposis Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Breakthrough Treatment for Desmoid Tumors Receives FDA Approval

The U.S. Food and Drug Administration (FDA) has officially approved Nirogacestat, a significant advancement for adult patients battling desmoid tumors. Desmoid tumors, which can arise in various parts of the body and tend to recur, have previously had limited treatment options. Nirogacestat, an oral therapy, is pivotal in managing these challenging tumors. By offering a non-invasive treatment alternative, Nirogacestat signifies hope for improved patient outcomes and highlights the progress in personalized cancer therapy. This approval underscores the FDA's commitment to fostering innovative treatments for complex diseases, promising a new horizon for patients and their families facing the trials of desmoid tumors. [Published On: 2023-11-28]

FDA Grants Orphan-Drug Designation to Therapyx's FAPXIL for Familial Adenomatous Polyposis Treatment

The United States Food and Drug Administration's (FDA) Office of Orphan Product Development has awarded Therapyx's experimental therapy, FAPXIL, with orphan-drug status for Familial Adenomatous Polyposis (FAP) treatment. FAP, a genetically inherited condition marked by the emergence of numerous adenomas in the colon and rectum, typically during adolescence, affects roughly 1 in 8,300 individuals at birth and impacts up to 50,000 Americans, irrespective of gender. This condition currently has no cure, making the development of FAPXIL a pivotal step in addressing the unmet medical needs of those living with FAP. [Published On: 2023-09-15]

Groundbreaking Clinical Trial for Familial Adenomatous Polyposis Receives FDA Go-Ahead

Eloxx Pharmaceuticals has obtained approval from the U.S. Food and Drug Administration (FDA) to commence a clinical trial aimed at tackling Familial Adenomatous Polyposis (FAP), a precancerous condition marked by the development of numerous polyps in the colon and rectum. The trial's approval underscores a critical advancement in clinical research, spotlighting Eloxx Pharmaceuticals' commitment to addressing unmet medical needs through innovative therapeutic approaches. This development represents a beacon of hope for patients grappling with FAP, offering a potential pathway to manage and possibly curtail the progression of this challenging condition. [Published On: 2023-05-02]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Familial Adenomatous Polyposis Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Familial Adenomatous Polyposis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Ambry Genetics Corporation, Amgen Inc., AstraZeneca PLC, Cellix Bio, Chugai Pharmaceutical Co., Ltd., Eli Lilly and Company, Eloxx Pharmaceuticals Inc., Emtora Biosciences, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Novartis AG, Panbela Therapeutics Inc., Pfizer Inc., Sanofi SA, Simson Pharma, SLA Pharma AG, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Familial Adenomatous Polyposis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Aspirin
    • CEQ-508
    • Eflornithine Hydrochloride
    • Icosapent
  • End-Users
    • Clinics & Hospitals
    • Diagnostic Centres
    • Home Healthcare
  • Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing concerns related to genetic disorders among populations and the need for effective treatment options
      • 5.1.1.2. Favorable government initiatives and reimbursement policies for colorectal cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Strict governments regulations for FAP drugs and cases of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Rapid pace of technological innovation in genetic testing and drug delivery system
      • 5.1.3.2. Investment in the research and development of new drugs and less invasive surgical techniqe
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of significant side effects associated with the FAP medicines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing preference for icosapent and aspirin as an anti-inflammatory medications in Familial Adenomatous Polyposis (FAP) treatment
    • 5.2.2. End-Users: Widening availability of Familial Adenomatous Polyposis treatment options through hospitals and diagnostic centers
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Familial Adenomatous Polyposis Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Aspirin
  • 6.3. CEQ-508
  • 6.4. Eflornithine Hydrochloride
  • 6.5. Icosapent

7. Familial Adenomatous Polyposis Treatment Market, by End-Users

  • 7.1. Introduction
  • 7.2. Clinics & Hospitals
  • 7.3. Diagnostic Centres
  • 7.4. Home Healthcare

8. Familial Adenomatous Polyposis Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Retail Pharmacy

9. Americas Familial Adenomatous Polyposis Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Familial Adenomatous Polyposis Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Familial Adenomatous Polyposis Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Breakthrough Treatment for Desmoid Tumors Receives FDA Approval
    • 12.3.2. FDA Grants Orphan-Drug Designation to Therapyx's FAPXIL for Familial Adenomatous Polyposis Treatment
    • 12.3.3. Groundbreaking Clinical Trial for Familial Adenomatous Polyposis Receives FDA Go-Ahead
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ASPIRIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CEQ-508, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CEQ-508, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY EFLORNITHINE HYDROCHLORIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY EFLORNITHINE HYDROCHLORIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ICOSAPENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ICOSAPENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLINICS & HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLINICS & HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTRES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTRES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023